These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Veenstra DL, Ramsey SD, Sullivan SD. Pharmacoeconomics; 2002; 20 Suppl 1():21-30. PubMed ID: 12036381 [Abstract] [Full Text] [Related]
5. Industry's perception of presenting pharmacoeconomic models to managed care organizations. Olson BM, Armstrong EP, Grizzle AJ, Nichter MA. J Manag Care Pharm; 2003; 9(2):159-67. PubMed ID: 14613345 [Abstract] [Full Text] [Related]
6. The use of pharmacoeconomic data in managed care: closing the credibility gap. Lewis BE. Manag Care Interface; 1997 Nov; 10(11):99-103. PubMed ID: 10174761 [Abstract] [Full Text] [Related]
10. Pharmacoeconomic analysis in formulary decisions: an international perspective. Johnson JA, Bootman JL. Am J Hosp Pharm; 1994 Oct 15; 51(20):2593-8. PubMed ID: 7847423 [Abstract] [Full Text] [Related]
12. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. Fry RN, Avey SG, Sullivan SD. Value Health; 2003 Oct 15; 6(5):505-21. PubMed ID: 14627057 [Abstract] [Full Text] [Related]
20. Use of health-related quality of life information in managed care formulary decision-making. Wu WK, Sause RB, Zacker C. Res Social Adm Pharm; 2005 Dec 14; 1(4):579-98. PubMed ID: 17138497 [Abstract] [Full Text] [Related] Page: [Next] [New Search]